Hormonal
Higher body mass index (BMI) exacerbates insulin resistance in women with PCOS more severely than in healthy controls, with a 10-unit increase in BMI associated with a 28% greater reduction in insulin sensitivity in PCOS compared to a 15% reduction in controls.
For women with PCOS, gaining weight has a more damaging effect on insulin sensitivity than it does for women without PCOS. This means weight management is critically important for PCOS patients, not just for appearance, but to mitigate the amplified metabolic risk. Maintaining a healthy weight is a key strategy to counteract the intrinsic insulin resistance.
A higher BMI exacerbated the reduction in IS by −15% (±8%; moderate, most likely lower) in PCOS compared with control women... a 10-unit higher BMI in women with PCOS was associated with a −28% (±14%; large, most likely) difference in IS. In control women, a 10-unit higher BMI resulted in a difference in IS of −15% (±17%; moderate, very likely lower).
Why this rating
Derived from the same robust meta-analysis of clamp studies.
Source
Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies
Samantha Cassar et al. · Human Reproduction · 2016
DOI 10.1093/humrep/dew243
More from this paper
- Women with polycystic ovary syndrome (PCOS) exhibit an intrinsic reduction in insulin sensitivity of approximately 27% compared to controls, a deficit that persists independently of body mass index (BMI), age, or diagnostic criteria.Strong
- Low levels of sex hormone-binding globulin (SHBG) are associated with reduced insulin sensitivity in women with PCOS, independent of BMI, suggesting SHBG may serve as a useful clinical marker for insulin resistance in this population.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →